Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia

Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia. Sylvia Boesch, Wolfgang Nachbauer, Caterina Mariotti, Francesco Sacca, Alessandro Filla, Thomas Klockgether, Thomas Klopstock, Ludger Schöls, Heike Jacobi, Boriana Büchner, Jennifer Müller vom Hagen, Lorenzo Nanetti and Karen Manicom. Movement Disorders, Article first published online: 11 FEB 2014 | DOI: 10.1002/mds.25836

CEPO was safe and well tolerated in a 2-week treatment phase. Secondary outcome measures remained without apparent difference between CEPO and placebo